Venner Shipley welcomes Brookes IP Read more
  • Great Britain
  • Germany
  • France
  • China
  • Souht Korea


Advising on IP in the pharmaceuticals se is one of our core disciplines and our attorneys have considerable expertise in dealing with all aspects of intellectual property in the pharmaceutical industry.

We are experienced in dealing with a diverse range of pharmaceutical subject matter, including: small molecule medicinal chemistry, protein & peptide chemistry, formulation chemistry, drug delivery, synthetic chemistry, chiral chemistry, polymorphic forms, dosage regimens and precision medicines. We have been successfully advising innovator and generic pharmaceutical companies for many years and have gained a reputation for providing a high quality, client-focused service. We have extensive experience in drafting and prosecuting applications for small molecule and biological pharmaceuticals, processes for preparing them, pharmaceutical formulations, and medical uses, as well as associated medical devices and diagnostics.

Oppositions and appeals

Contentious proceedings frequently arise in this highly competitive field, and we are regularly entrusted with handling oppositions and appeals relating to high value pharma patents where the commercial stakes are high. Our opposition and appeal specialists are European patent attorneys who are regularly involved in these proceedings before the European Patent Office and have a long track record of achieving excellent outcomes for our clients. The team’s technical expertise and procedural knowledge, combined with their oral advocacy skills, ensure the best possible outcome and they are adept at acting either offensively or defensively, as required.

Supplementary Protection Certificates

SPCs are national rights that extend the protection afforded by a patent for the active ingredient(s) of a medicinal or plant protection product by up to five and a half years. Our life sciences team has been filing and prosecuting SPC applications since the inception of the European SPC Regulations in the 1990s. We have extensive experience in advising clients on applying for SPCs and SPC extensions, and providing strategic advice regarding SPC strategy for pharmaceutical and plant protection products based on all possible basic patents and relevant marketing authorisations. We have also successfully challenged the validity of SPCs filed by third parties. In addition to acting before the UK Intellectual Property Office, which is responsible for granting SPCs in the UK, we can coordinate SPC filing programmes throughout the EU and EEA.

  • Europe’s Leading Patent Law Firms 2022 by the Financial Times

  • Patently Obvious? The English High Court Considers Drug Development Practices in Teva v Bayer

  • Health Enterprise East: Clinical Innovators Forum

  • Financial Time’s, Europe’s Leading Patent Law Firms 2021

  • BIO Korea 2021

  • Kymab prevails as the UK Supreme Court affirms the requirement for sufficient disclosure

  • Kymab prevails as the Supreme Court affirms the requirement for sufficient disclosure

  • Primed and ready (or not)—Arnold LJ warns patent profession (Akebia Therapeutics v Fibrogen)

  • Patient consent and the GDPR: what does it mean for clinical trials and research?